


IFW/1645

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))</b>					Docket No. 19181
In Re Application Of: Sandra Ebert, et al.					
					
Application No.	Filing Date	TRADEMARK EXAMINER	Customer No.	Group Art Unit	Confirmation No.
10/549,557	September 19, 2005	Unassigned	23389	Unassigned	4680
Title: <b>ASSESSMENT METHOD</b>					
Address to: <b>Commissioner for Patents</b> P.O. Box 1450 Alexandria, VA 22313-1450					
<b>37 CFR 1.97(b)</b>					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
<b>37 CFR 1.97(c)</b>					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
<b>OR</b>					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
**19181**

In Re Application of: Sandra Ebert, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/549,557	September 19, 2005	Unassigned	23389	Unassigned	4680

Title:

**ASSESSMENT METHOD**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \_\_\_\_\_ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
  - Charge the amount of \_\_\_\_\_
  - Credit any overpayment.
  - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

*[Signature]*  
 Typed or Printed Name of Person Signing Certificate

\*This certificate may only be used if paying by deposit account.

*[Signature]*  
 Signature

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, PC  
 400 Garden City Plaza, Suite 300  
 Garden City, New York 11530  
 (516) 742-4343

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 26, 2007

*[Signature]*  
 Signature of Person Mailing Correspondence  
 Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

Dated: January 26, 2007

cc: XZ:bk



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Sandra Ebert, et al.  
**Serial No.:** 10/549,557  
**Filed:** September 19, 2005  
**For:** ASSESSMENT METHOD

**Examiner:** Unassigned  
**Art Unit:** Unassigned  
**Docket:** 19181  
**Dated:** January 26, 2007

Mailstop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. Michel, Uwe, et al., "Serum follistatin concentrations are increased in patients with septicaemia" Chemical Endocrinology, Vol. 48, pp 413-417.
2. Hübner, Griseldism, "Activin A: A novel player and inflammatory marker in inflammatory bowel disease?" Laboratory Investigation, Vol. 77 (4), pp. 311-318.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mailstop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 26, 2007.

Dated: January 26, 2007



Xiaochun Zhu

3. Jones, K.L., et al., "Activin A release into the circulation is an early event in systematic inflammation and precedes the release of follistatin"; Endocrinology, Vol. 141 (5), pp. 1905-1908.
4. De Kreseter, D.M. ,et al., "Activin A and follistatin: their role in the acute phase reaction and inflammation", Journal of Endocrinology, Vol. 161, pp. 195-198.

The references were cited in an International Search Report dated May 13, 2004, an European Search Report dated February 26, 2006, as well as a New Zealand Patent Appln. No. 542364 Examination Report dated June 15, 2006. Applicants are submitting copies of the above-cited references required by 37 C.F.R. 1.98 (a)(2)(i) and (ii), together with a copy of each of the International Search Report, European Search Report and New Zealand Examination Report. The relevance of the above-identified references has been described in the International Search Report.


Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Xiaochun Zhu  
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza - Ste. 300  
Garden City, New York 11530  
(516) 742-4343  
XZ:bk

<b>INFORMATION DISCLOSURE CITATION</b> <small>(Use several sheets if necessary)</small>  <b>JAN 30 2007</b>			ATTY DOCKET NO. <b>19181</b>	APPLICATION NO. <b>10/549,557</b>		
			APPLICANT(S) <b>Sandra Ebert, et al.</b>			
			FILING DATE <b>September 19, 2005</b>	GROUP ART UNIT <b>Unassigned</b>		
<b>U.S. PATENT DOCUMENTS</b>						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
		Michel, Uwe, et al., "Serum follistatin concentrations are increased in patients with septicaemia" Chemical Endocrinology, Vol. 48, pp 413-417.				
		Hübner, Griseldis, "Activin A: A novel player and inflammatory marker in inflammatory bowel disease?" Laboratory Investigation, Vol. 77 (4), pp. 311-318.				
EXAMINER			DATE CONSIDERED			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>						

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY DOCKET NO. 19181		APPLICATION NO. 10/549,557			
			Sandra Ebert, et al.					
			FILING September 19, 2005	GROUP ART Unassigned				
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		Jones, K.L., et al., "Activin A release into the circulation is an early event in systematic inflammation and precedes the release of follistatin"; Endocrinology, Vol. 141 (5), pp. 1905-1908.						
		De Kreseter, D.M. ,et al., "Activin A and follistatin: their role in the acute phase reaction and inflammation", Journal of Endocrinology, Vol. 161, pp. 195-198.						
EXAMINER			DATE CONSIDERED					
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>								